X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs TEVA PHARMA (Israel) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 CIPLA   TEVA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-18
TEVA PHARMA
Dec-13
CIPLA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6633,072-   
Low Rs4792,669-   
Sales per share (Unadj.) Rs189.01,763.1-  
Earnings per share (Unadj.) Rs17.6110.1-  
Cash flow per share (Unadj.) Rs34.0252.7-  
Dividends per share (Unadj.) Rs3.0096.42-  
Dividend yield (eoy) %0.53.4 15.6%  
Book value per share (Unadj.) Rs176.71,958.5-  
Shares outstanding (eoy) m805.12848.00-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.6 185.5%   
Avg P/E ratio x32.526.1 124.5%  
P/CF ratio (eoy) x16.811.4 147.7%  
Price / Book Value ratio x3.21.5 220.4%  
Dividend payout %17.187.5 19.5%   
Avg Mkt Cap Rs m459,7242,434,099 18.9%   
No. of employees `00023.644.9 52.5%   
Total wages/salary Rs m26,9010-   
Avg. sales/employee Rs Th6,446.133,265.3 19.4%   
Avg. wages/employee Rs Th1,139.40-   
Avg. net profit/employee Rs Th600.02,078.1 28.9%   
INCOME DATA
Net Sales Rs m152,1931,495,110 10.2%  
Other income Rs m3,5770-   
Total revenues Rs m155,7691,495,110 10.4%   
Gross profit Rs m28,264409,437 6.9%  
Depreciation Rs m13,228120,851 10.9%   
Interest Rs m1,14229,366 3.9%   
Profit before tax Rs m17,470259,219 6.7%   
Minority Interest Rs m01,178 0.0%   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-775-170,163 0.5%   
Tax Rs m2,501-3,165 -79.0%   
Profit after tax Rs m14,16693,398 15.2%  
Gross profit margin %18.627.4 67.8%  
Effective tax rate %14.3-1.2 -1,172.6%   
Net profit margin %9.36.2 149.0%  
BALANCE SHEET DATA
Current assets Rs m108,1411,009,792 10.7%   
Current liabilities Rs m38,322880,624 4.4%   
Net working cap to sales %45.98.6 531.0%  
Current ratio x2.81.1 246.1%  
Inventory Days Days9791 106.8%  
Debtors Days Days7496 77.6%  
Net fixed assets Rs m109,411488,336 22.4%   
Share capital Rs m1,6103,680 43.8%   
"Free" reserves Rs m140,6820-   
Net worth Rs m142,2921,660,784 8.6%   
Long term debt Rs m36,621764,483 4.8%   
Total assets Rs m228,6063,416,806 6.7%  
Interest coverage x16.39.8 165.8%   
Debt to equity ratio x0.30.5 55.9%  
Sales to assets ratio x0.70.4 152.1%   
Return on assets %6.73.6 186.4%  
Return on equity %10.05.6 177.0%  
Return on capital %10.04.9 201.8%  
Exports to sales %32.80-   
Imports to sales %00-   
Net fx Rs m30,6580-   
CASH FLOW
From Operations Rs m14,628238,243 6.1%  
From Investments Rs m-8,540-84,419 10.1%  
From Financial Activity Rs m-3,855-285,789 1.3%  
Net Cashflow Rs m2,431-131,965 -1.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.6 Rs / USD

Compare CIPLA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare CIPLA With: MERCK LTD  ALEMBIC PHARMA  VENUS REMEDIES  FRESENIUS KABI ONCO.  IPCA LABS  



Today's Market

Sensex Ends Over 450 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued their sell-off seen during the day and ended the trading session deep in the red. All sectoral indices traded on a negative note with stocks in the IT sector.

Related Views On News

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

My Top 3 Tips to Navigate the Market Crash(The 5 Minute Wrapup)

Oct 8, 2018

Steep corrections are never easy to handle. It's hard to watch the value of your shares drop so much. But you can take steps to make the most of it.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)

Oct 12, 2018

Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.

ICICI Prudential Manufacture In India Fund: A Make In India Prodigy, Should You Invest?(Outside View)

Oct 8, 2018

PersonalFN briefly explains if you should be investing in the NFO: ICICI Prudenetial Manufacture in India Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 19, 2018 03:35 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS